Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 100 results for bladder cancer

  1. Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer TSID 12021

    Awaiting development [GID-TA11556] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. The evidence on the safety of transurethral laser ablation for recurrent non-muscle-invasive bladder cancer shows that there are no major safety concerns. However, current evidence on its efficacy is limited in quality and quantity. Therefore, this procedure should only be used with  special arrangements   for clinical governance, consent, and audit or research.

    safety of transurethral laser ablation for recurrent non-muscle-invasive bladder cancer shows that there are no major safety concerns....

    Research recommendation
    Published
    15 November 2019

  3. Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)

    This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.

    NICE guideline
    Published
    6 July 2016
    View recommendations

    Sections for NG49

  4. Is symptom-based review as effective as scheduled follow-up for people treated with radical cystectomy or radical radiotherapy for organ-confined, muscle-invasive bladder cancer? Outcomes of interest are overall survival, health-related quality of life, resource use and cost.

    cystectomy or radical radiotherapy for organ-confined, muscle-invasive bladder cancer? Outcomes of interest are overall survival,...

    Research recommendation
    Published
    9 June 2015

  5. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development [GID-TA11137] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Pelvic floor dysfunction: prevention and non-surgical management (NG210)

    This guideline covers the prevention, assessment and non-surgical management of pelvic floor dysfunction in women aged 12 and over. It aims to raise awareness and help women to reduce their risk of pelvic floor dysfunction. For women who have pelvic floor dysfunction, the guideline recommends interventions based on their specific symptoms.

    NICE guideline
    Published
    9 December 2021
    View recommendations

    Sections for NG210

  7. Irritable bowel syndrome in adults: diagnosis and management (CG61)

    This guideline covers diagnosing and managing irritable bowel syndrome (IBS) in people aged 18 and over. It details how to accurately diagnose IBS, and aims to improve the quality of life for adults with IBS by promoting effective management using dietary and lifestyle advice, pharmacological therapy and referral for psychological interventions.

    Clinical guideline
    Last updated
    4 April 2017
    View recommendations

    Sections for CG61

  8. Laparoscopic cystectomy (IPG287)

    Evidence-based recommendations on laparoscopic cystectomy. This involves removing the bladder using small cuts in the abdomen (keyhole surgery).

    Interventional procedures guidance
    Published
    25 February 2009
    View recommendations

    Sections for IPG287

  9. Lower urinary tract symptoms in men (QS45)

    This quality standard covers diagnosing and managing lower urinary tract symptoms in men (aged 18 and over). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    18 September 2013
    View quality statements

    Sections for QS45

  10. NICE encourages further research into intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer. Research should include randomised controlled trials, which stratify patients by risk and give adequate follow-up. They should report frequency of adverse events, patientreported outcome measures, overall and disease-free survival and quality of life.

    intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer. Research should include randomised...

    Research recommendation
    Published
    12 December 2018

  11. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]

    Awaiting development [GID-TA11338] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development [GID-TA11517] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]

    Awaiting development [GID-TA11654] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Spinal metastases and metastatic spinal cord compression (QS56)

    This quality standard covers diagnosis and management of spinal metastases and metastatic spinal cord compression. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    6 September 2023
    View quality statements

    Sections for QS56

  15. Irritable bowel syndrome in adults (QS114)

    This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    11 February 2016
    View quality statements

    Sections for QS114